24-hour ECG, and cardiac biomarkers. 6, [12] [13] [14] [15] [16] However, dogs in stage 1 cannot be diagnosed by the gold standard methods, echocardiography and 24-hour ECG. Cardiac troponin I (cTnI) concentration measurement is a valuable additional screening test for diagnosis at this early stage using a conventional cTnI assay. Using this conventional cTnI assay, a cutoff value of >0.22 ng/mL has a sensitivity of 79.5% and a specificity of 84.4% to detect all DCM disease stages. 14 Cardiac troponin I is a highly sensitive and specific marker of myocardial injury and correlates with the severity of myocardial damage. 17, 18 The development of high-sensitivity cTnI (hs-cTnI) assays in human medicine allows to detect lower cTnI concentrations compared with conventional cTnI assays. Therefore, the detection of mild myocardial injury, as it occurs in the early stages of myocardial diseases, is now possible. 19, 20 Furthermore, in veterinary medicine, studies showed the feasibility and suitability of hs-cTnI assays for recognition of myocardial damage, too. [21] [22] [23] [24] [25] However, there is currently only 1 abstract available, which used an hs-cTnI to detect DCM in DP with DCM. 26 Therefore, the objectives of this study were (1) to evaluate an hscTnI assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics, Eschborn, Germany) analytically and clinically as a screening test for early stages of DCM in DP; (2) to provide cutoff values to detect DP with DCM using an hs-cTnI assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics); and (3) to perform a test comparison between an hs-cTnI assay (Advia Centaur TnI-Ultra assay;
Siemens Healthcare Diagnostics) and a conventional cTnI assay (Immulite 2000 troponin I test; Siemens Healthcare Diagnostics, Eschborn, Germany).
| MATERIALS AND METHODS

| Animals
The study population comprised 341 privately owned purebred DP that were selected from a continuing prospective longitudinal study, according to the inclusion and exclusion criteria. Overall 524 examinations at different time points from 341 DP were included in the study.
| Inclusion criteria
Doberman Pinschers were selected if they fulfilled 1 of the group criteria as described below. For healthy DP, at least 1 follow-up examination after 1 year needed to be available.
| Exclusion criteria
Dogs were excluded if they could not be precisely matched into 1 of the 6 groups. Therefore, DP with 50-300 VPC/24 hours once a year or dogs with unclear borderline echocardiographic measurements were considered to be "equivocal" and were excluded from the study.
Doberman Pinschers diagnosed with relevant systemic diseases, congenital or acquired heart diseases other than DCM, were excluded.
Furthermore, DP with increased urea concentrations, creatinine concentrations, or both were excluded from the study to avoid falsely increased concentrations of cTnI.
| Examinations
Medical history was gathered and a complete examination was performed both at first presentation and at every control examination.
Healthy DP were examined at least once a year. Doberman Pinschers with an increased cTnI concentration (using a conventional cTnI assay; Siemens Healthcare Diagnostics) with a detection limit of 0.2 ng/mL (measuring range 0.2-180 ng/mL). Remaining serum and EDTAplasma samples were stored in batches at −80 C until being shipped on dry ice to the same external laboratory (IDEXX Laboratories) for the determination of the cTnI concentrations from serum and EDTA-plasma by the hs-cTnI assay (Advia Centaur TnI-Ultra assay;
Siemens Healthcare Diagnostics). The hs-cTnI assay is a secondgeneration sandwich immunoassay using 3 different antibodies and direct chemiluminometry. The detection limit of this assay is 0.006 ng/mL (measuring range 0.006-50 ng/mL). Urea and creatinine concentrations were measured in-house (Cobas Integra 400 plus; Roche Diagnostics, Rotkreuz, Switzerland).
| Allocation
Dogs were allocated into 1 of the 6 groups based on the following criteria. 3 | RESULTS
| Dog characteristics
Overall, 524 examinations of 341 DP (170 female and 171 male) met the inclusion criteria. The healthy group consisted of 179 DP, and results of the latest examination were used for statistical analyses in this group. One hundred sixty-two DP (69 female and 93 male) were diagnosed with DCM, and results of each available examination (345 examinations) were used for statistical analyses. Table 1 shows characteristics of groups, results of echocardiographic measurements, and the number of VPC in 24 hours.
Doberman Pinschers in the VPC group were significantly older than dogs in the healthy group (P < .001), ECHO group (P < .001), and last-normal group (P < .001). Dogs in the ECHO group were significantly younger than dogs in the healthy group (P < .001), VPC group (P < .001), and ECHO-and-VPC group (P < .001). Furthermore, dogs in the last-normal group were significantly younger than dogs in the ECHO-and-VPC group (P < .001).
3.2 | Analytical evaluation of the hs-cTnI assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) and analytical test comparison between the hs-cTnI assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) and the conventional cTnI assay (Immulite 2000 troponin I test; Siemens Healthcare Diagnostics)
The mean intra-assay CV of the hs-cTnI assay was 2.8% and the mean inter-assay CV was 5.5% (Table 2) . To assess the conformity between hs-cTnI concentrations obtained from serum and EDTA tubes, 128 paired blood samples of 64 DP (64 serum samples, 64 EDTA samples) were available. At the beginning of the study, these 64 DP were randomly selected and for these dogs, both serum and plasma samples were available. High-sensitivity cTnI concentration was measured in each sample using the hs-cTnI assay (Advia Centaur TnI-Ultra assay;
Siemens Healthcare Diagnostics) and resulted in a mean serum cTnI Abbreviations: CHF, congestive heart failure; CTnI, cardiac troponin I; CV, coefficient of variation; hs-cTnI, high-sensitivity cTnI; VPC, ventricular premature complexes. Healthcare Diagnostics) was statistically significant (P < .0001).
3.3 | Clinical evaluation of the hs-cTnI assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) using EDTA-plasma
The relationship between age and cTnI concentration was evaluated using a linear regression analysis in 179 healthy DP (Figure 3 ). Despite only a weak association between age and cTnI concentration (R 2 = 0.095), older dogs had significantly higher EDTA-plasma hs-cTnI concentrations (P < .001). There was no difference between the hscTnI concentration from healthy male (mean = 0.095 ng/mL) and female (mean = 0.087 ng/mL) dogs (P = .91). Table 3 shows EDTA-plasma hs-cTnI concentrations of each group. The following statistically significant differences between the mean hs-cTnI concentrations of these groups were detected: DP in the healthy group had a lower mean hs-cTnI concentration than DP in all other groups (P < .001), including the last-normal group. DP in the ECHO-and-VPC group had a higher mean cTnI concentration than dogs in the ECHO group (P < .001), last-normal group (P = .002), and healthy group (P < .001). Furthermore, dogs in the CHF group had a significantly higher mean cTnI concentration than dogs in all other groups (P < .001) (Figure 4 ).
3.4
| Cutoff values for detection of DP with DCM using an hs-cTnI assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) and EDTA-plasma
Several cutoff values for overall DCM diagnosis and for subgroups were tested by using ROC curves. With a cutoff value of hs-cTnI concentration >0.113 ng/mL, sensitivity was 81.2%, specificity was 73.2%
and AUC was 0.835 for detection of DCM in DP. The prevalence of DCM in the current population was 65.8%. Concerning DP in the lastnormal group, 72% (21/29) of these dogs were presumed to be affected by DCM when using an hs-cTnI concentration >0.113 ng/mL as cutoff value. With a higher cutoff value of hs-cTnI concentration >0.242 ng/mL to identify all DCM stages, including dogs in the lastnormal group, it had increased specificity but only a low sensitivity (sensitivity 42.3%, specificity 97.2%). The AUC for prediction of VPC (AUC = 0.862) was similar to the AUC for prediction of echocardiographic changes (AUC = 0.838). Sensitivity, specificity, and AUC of hscTnI concentration cutoff values to predict DCM, only echocardiographic changes, or only arrhythmias in DP are shown in Table 4 . There was no statistically significant association between the hs-cTnI concentration and the number of VPC in 24 hours (R 2 = 0.013; P = . 22) for DP with arrhythmias. The multiple regression analysis showed a statistically significant influence (P < .001) of disease stage and age on cTnI concentration. The influence of sex was statistically not significant.
FIGURE 3
Relationship between age and EDTA-plasma cTnI concentration (ng/mL) in healthy Doberman Pinschers using an hs-cTnI assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) (P < .001). CTnI, cardiac troponin I; EDTA, ethylendiaminetetraacetic acid; hs-cTnI, high-sensitivity cTnI (18/29), DP in the last-normal group were presumed to be affected by DCM. The AUC, sensitivity, and specificity for prediction of DCM, arrhythmias, or echocardiographic changes are displayed in Table 4 .
A comparison of the ROC curves obtained from the hs-cTnI assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) and the conventional cTnI assay (Immulite 2000 troponin I test; Siemens Healthcare Diagnostics) showed no statistically significant difference (P = .07). 
| DISCUSSION
Cardiac troponin I is an important marker of myocardial damage. This prospective study evaluated an hs-cTnI assay analytically and clinically as a screening test for various stages of DCM in DP and provided cutoff values for detection of DP with DCM. With a cutoff value of hs-cTnI concentration of >0.113 ng/mL, the presence of DCM in DP was presumed with a good sensitivity. Therefore, in combination with the gold standard examinations, echocardiography and 24-hour ECG, this hs-cTnI cutoff value might be used for DCM screening purposes. With higher cutoff values, for example, hs-cTnI concentration >0.242 ng/mL, the specificity to detect all DCM disease stages increased. If DP have an hs-cTnI concentration above this cutoff value, the high specificity indicates that the dogs have DCM with a high probability. However, it is important to acknowledge that cTnI can increase with a variety of noncardiac diseases, such as gastric dilatation volvulus, 32 canine babesiosis, 33 kidney diseases, 34 pulmonary hypertension, 35 and systemic inflammatory response syndrome. 36 In our study, the included dogs did not have clinical signs, with the exception of the clinical group, and there was no evidence of pulmonary hypertension detectable on echocardiography.
Therefore, it is recommended to use the suggested cutoff values for screening purposes only in clinically normal dogs, without evidence of a systemic disease. Accordingly, statistical ROC analysis was repeated after exclusion of DP with CHF (with clinical signs) and results showed the same specificity and a similar but a slightly lower sensitivity for detection of DP with occult DCM.
Gold standard examinations for the diagnosis of DCM are a combination of echocardiography and 24-hour ECG. In this study, DP in the last-normal group showed a normal echocardiographic and 24-hour ECG examination. Therefore, at the time of the first examination, dogs in this group were considered to be healthy according to the gold standard examinations. These dogs were included into the last-normal group retrospectively when they were diagnosed with DCM on the following examination.
The optimal cutoff value for the conventional cTnI test (Immulite 2000 troponin I test; Siemens Healthcare Diagnostics) was the same as previously published (>0.22 ng/mL 14 ) for detection of DP with DCM and showed a similar sensitivity but a slightly lower specificity in this study population in comparison to the cited study. 14 Therefore, this study confirms the previously published cutoff value of cTnI concentration >0.22 ng/mL using a conventional cTnI assay (Immulite 2000 troponin I test; Siemens Healthcare Diagnostics).
The comparison between the hs-cTnI assay (Advia Centaur TnIUltra assay; Siemens Healthcare Diagnostics) and conventional cTnI assay (Immulite 2000 troponin I test; Siemens Healthcare Diagnostics) indicated a similar good test performance for prediction of DCM in DP ( Figure 5 and Table 4 ). Nevertheless, a better detection rate of DP in the last-normal group (DP with DCM stage 1) was reached using the hs-cTnI assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics). Accordingly, more dogs with DCM stage 1 could be identified using an hs-cTnI assay, indicating less advanced disease.
This advantage might be attributed to the lower detection limit of the hs-cTnI assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics). Earlier detection of DCM in DP by using cTnI concentration measurement in comparison to echocardiography and 24-hour ECG corroborates the findings of other studies in veterinary 14 and human 37 medicine.
This prospective study showed that the detection of mild myocardial injury in DP, as it occurs in early stages of DCM, is possible and feasible, by using an hs-cTnI assay (Advia Centaur TnI-Ultra assay;
Siemens Healthcare Diagnostics) or alternatively by using the conven- Comparison of ROC curves obtained from an hs-cTnI assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) (using EDTA-plasma) and a conventional cTnI assay (Immulite 2000 troponin I test; Siemens Healthcare Diagnostics) (using serum) to detect occult DCM in Doberman Pinschers. CTnI, cardiac troponin I; EDTA, ethylendiaminetetraacetic acid; hs-cTnI, high-sensitivity cTnI; ROC, receiver operator curves TnI-Ultra assay; Siemens Healthcare Diagnostics). This is graphically depicted on the Bland-Altman plot (Figure 2 ), which shows a random difference between the 2 assays, and it therefore illustrates that the 2 assays cannot be used interchangeably. Accordingly, for follow-up and diagnostic purposes, it is recommended to use the same assay and different cutoff values.
Currently, only a few studies evaluated the suitability of an hscTnI assay for detection of early myocardial damage in animals, [21] [22] [23] [24] [25] and there is only 1 study published as an abstract evaluating an hs-cTnI assay in DP. 26 This study in 449 DP reported an hs-cTnI cutoff >0.139 ng/mL (ADVIA Centaur CP Ultra-TnI) and had a 100% sensitivity and 79% specificity to detect the characteristic echocardiographic morphologic changes of DCM with or without concurrent evidence of VPC on a 3-minute ECG. 26 The calculated cutoff value (>0.139 ng/mL) of this study is very similar to the cutoff value of our study (>0.113 ng/mL) but had a better sensitivity and specificity than in our study. The difference between the results might be explained by the low number of dogs with DCM (n = 22) in the cited study, presumably leading to a higher variation. Furthermore, no Holter examination was performed and no SMOD was used for detection of DP with DCM in the cited study. Because SMOD is better for detection of DCM in DP in comparison to M-mode measurements 28 and Holter examination is necessary for diagnosis of DCM 16 , this study (and the lower hs-cTnI cutoff value) potentially detected more DP with occult DCM in comparison to the cited study.
Nevertheless, using hs-cTnI assays might lead to an earlier detection of DCM in DP, and dogs with increased hs-cTnI concentrations could benefit from earlier control examinations (such as recheck after 6 months) compared to the recommendation of yearly reexaminations. 16 In a similar manner, in human medicine, the application of hscTnI assays is associated with a major progress in early recognition of patients with acute coronary syndrome 38 and helps defining which patient would benefit from early invasive management. [39] [40] [41] [42] The international recommendations 43, 44 for test precision (CV <10%) were fulfilled, and inter-assay variability as well as intraassay variability revealed similar results as described previously for cattle, cats, and dogs with different cardiac diseases. 21, 23, 25 The proposed hs-cTnI cutoff concentration 0.113 ng/mL is lower than the concentration of the samples used for validation, and the majority of dogs in this study had hs-cTnI concentrations lower than the samples used for validation. However, the hs-cTnI (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) assay has been evaluated in a previous study using high and low cTnI serum pools with intra-and inter-assay CVs ranging from 3.9% to 6.4% and from 2.7% to 4.7%, respectively. 21 Therefore, the samples used for validation of the hs-cTnI assay (Advia Centaur TnI-Ultra assay; Siemens Healthcare Diagnostics) in the present study should be seen as supplements to the cited study. 21 The assessment of the conformity between hs-cTnI concentrations obtained from serum and EDTA tubes showed a mean difference of 0.03 ng/mL, which was statistically not significant. Therefore, serum as well as EDTA blood can be used for hs-cTnI measurement.
Some authors described that ionized calcium, which is required to maintain cTnI complexes, is removed by chelation of metal ions, when using EDTA tubes. 45 This might be a cause for the detection of lower cTnI concentration in EDTA tubes.
In this study, the AUC for prediction of arrhythmias was similar to the AUC for prediction of echocardiographic changes. It is presumed that myocardial damage is more relevant in connection with arrhythmias than in connection with echocardiographic changes. 46 However, results of another study suggested a better prediction of echocardiographic changes in contrast to the prediction of VPC and contradicts this presumption. 14 47 The initiation of treatment of systolic dysfunction is based on echocardiography. 48 However, cTnI concentration measurement is a simple, feasible, low-cost, and useful screening test for DCM in DP. Doberman Pinschers with hs-cTnI concentrations >0.113 ng/mL should be investigated using gold standard examinations (echocardiography and 24-hour ECG). Furthermore, DP with a negative assay result (hs-cTnI concentration <0.113 ng/mL) should be examined using gold standard examinations as well, not to miss DCM.
In this study, age had a statistically significant influence on healthy DP, that is, older dogs showed higher hs-cTnI concentrations.
This is in accordance with other studies suggesting that an age-related remodeling of the myocardium leads to increased cTnI concentrations. 14, 17, 46 There was no influence of sex on hs-cTnI concentration in this study population, as likewise described in another study. 14 
| Study limitations
It cannot be ruled out that healthy dogs (according to gold standard examinations) with an increased cTnI concentration were in an early stage of DCM, which presents a limitation of this study. It is possible that some of these dogs might develop DCM or that the concentra- might lead to identification of DP with DCM.
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